Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Switching to doravirine-based antiretroviral therapy without genotypic resistance tests in virologically suppressed people with HIV.

AIDS (London, England) - 1 Aug 2026

Mason James, Kohli Manik, Taiwo Ebun, Maan Irfaan, Gharib Yomna, Suonpera Emmi, Barlow Maeve, Olcott Flora, Waters Laura, Arenas-Pinto Alejandro, Gilson Richard, Pett Sarah

Abstract excerpt

BACKGROUND: Doravirine is a non-nucleoside reverse transcriptase inhibitor (NNRTI) recommended for first-line antiretroviral therapy (ART), and for suppressed switching, in combination with a two nucleos(t)ide reverse transcriptase inhibitor (NRTI) backbone. Doravirine does not have a high barrier to resistance, and genotypic resistance testing (GRT) preswitch is recommended. Data on its use without preswitching...

Topics

Join the communities discussing this publication.

Anti-HIV Agents
Anti-Retroviral Agents
Drug Substitution
Genotyping Techniques
London

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Sustained Virologic Response

Source

Open in PubMed Open full text

Identifiers

PMID: 41921081
DOI: 10.1097/QAD.0000000000004508
PMCID: PMC13336751

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 1 Sept 2026.

Community interpretation

Discuss the evidence

Ask a question, add context or challenge an interpretation. Community activity is separate from scientific evidence strength.

0

discussions

0

replies

Citations encouraged

Claims remain attributable.

No discussion yet

Be the first to add a careful, cited interpretation.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Switching to doravirine-based antiretroviral therapy without genotypic resistance tests in virologically suppressed people with HIV.PMID 41921081Read ↗

No virological failure in patients living with HIV with past NNRTI resistance-associated mutations switched to doravirine-containing regimensSemantic proximity Read ↗

DORAVIR: a French national survey of people with HIV-1 treated with an antiretroviral regimen including doravirine.Semantic proximity Read ↗

Doravirine Resistance Patterns Identified Through Week 192 in the DRIVE-FORWARD and DRIVE-AHEAD Phase 3 Clinical Trials.Semantic proximity Read ↗

Potential role of doravirine for the treatment of HIV-1-infected persons with transmitted drug resistance.Semantic proximity Read ↗

Impact of HIV-1 Resistance-Associated Mutations on Susceptibility to Doravirine: Analysis of Real-World Clinical Isolates.Semantic proximity Read ↗

Is there a role for doravirine in African HIV treatment programmes? A large observational resistance study in South Africa.Semantic proximity Read ↗

Residual phenotypic susceptibility to doravirine in multidrug-resistant HIV-1 from subjects enrolled in the PRESTIGIO Registry.Semantic proximity Read ↗

Potential Role of Doravirine for the Treatment of Patients with Transmitted Drug ResistanceSemantic proximity Read ↗

Emerging reverse transcriptase inhibitors for HIV-1 infectionSemantic proximity Read ↗

Low prevalence of doravirine-associated resistance mutations among polish human immunodeficiency-1 (HIV-1)-infected patients.Semantic proximity Read ↗

Prevalence of predicted resistance to doravirine in HIV-1-positive patients after exposure to non-nucleoside reverse transcriptase inhibitorsSemantic proximity Read ↗

Doravirine and Islatravir Have Complementary Resistance Profiles and Create a Combination with a High Barrier to Resistance.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.